Oncocyte enters amended CEO employment agreement with Joshua Riggs; grants 1.15M options

Insight Molecular Diagnostics Inc.

Base salary $360,000, target bonus 50% of base salary, effective May 1, 2023.
CEO Grant: options to purchase 350,000 shares, 25% vests at 1 year, balance monthly over 3 years.
Performance Grant: options for 800,000 shares, vesting tied to VWAP targets ($0.54-$1.08) by Dec 31, 2025.
Severance includes 12 months base salary, pro-rated bonus, health premium if terminated without cause or for good reason.
Riggs appointed CEO Feb 24, 2023; this agreement amends and restates prior agreements.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joshua Riggs

Chief Executive Officer

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2023-02-24
Filed: June 9, 2023, 7:59 PM ET

On March 2, 2023, Oncocyte Corporation (the “Company”) issued a press release announcing that Joshua Riggs, the Interim Chief Executive Officer of the Company, was appointed the Chief Executive Officer of the Company, effective February 24, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joshua Riggs was appointed as Chief Executive Officer at Insight Molecular Diagnostics Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On March 2, 2023, Oncocyte Corporation (the “Company”) issued a press release announcing that Joshua Riggs, the Interim Chief Executive Officer of the Company, was appointed the Chief Executive Officer of the Company, effective February 24, 2023

View on SEC.gov

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-020623

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.